Latest market price
89.54
+1.62+1.84%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | 0.37 | Insider Own | 8.83% | Shs Outstand | 9.36M | Perf Week | 5.51% |
| Market Cap | 822.91M | Forward P/E | 40.44 | EPS next Y | 2.17 | Insider Trans | -0.82% | Shs Float | 9.13M | Perf Month | -2.73% |
| Enterprise Value | 953.91M | PEG | 14.14 | EPS next Q | 0.45 | Short Float | 4.84% | Perf Quarter | -4.32% | ||
| Income | 3.00M | P/S | 2.36 | EPS this Y | 4.61% | Short Ratio | 3.64 | Perf Half Y | 24.59% | ||
| Sales | 348.00M | P/B | 2.72 | EPS next Y | 14.66% | ROA | 0.70% | Short Interest | 441.86K | Perf YTD | 54.98% |
| Book/sh | 32.37 | P/C | 117.56 | EPS next 5Y | 16.81% | ROE | 1.15% | 52W High | 100.00 -10.46% | Perf Year | 19.00% |
| Cash/sh | 0.75 | P/FCF | 32.92 | EPS past 3/5Y | -25.88% -11.16% | ROIC | 1.41% | 52W Low | 50.23 78.26% | Perf 3Y | -6.00% |
| Dividend Est. | — | EV/EBITDA | 24.46 | Sales past 3/5Y | 12.85% 13.92% | Gross Margin | 32.50% | Volatility | 3.41% 3.28% | Perf 5Y | 20.44% |
| Dividend TTM | — | EV/Sales | 2.74 | EPS Y/Y TTM | -77.71% | Oper. Margin | 3.02% | ATR (14) | 3.35 | Perf 10Y | 726.28% |
| Dividend Ex-Date | — | Quick Ratio | 2.11 | Sales Y/Y TTM | 20.00% | Profit Margin | 0.99% | RSI (14) | 53.94 | Recom | 2.10 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.49 | EPS Q/Q | -76.27% | SMA20 | 3.09% | Beta | 0.64 | Target Price | 123.60 |
| Payout | 0.00% | Debt/Eq | 0.46 | Sales Q/Q | 20.78% | SMA50 | 2.17% | Rel Volume | 1.01 | Prev Close | 87.92 |
| Employees | 1,413 | LT Debt/Eq | 0.46 | Earnings | Nov 03 | SMA200 | 7.51% | Avg Volume | 130.37K | Price | 89.54 |
| IPO Date | Dec 05, 1977 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -62.91% 7.39% | Net Debt/EBITDA | 3.36 | Volume | 132,115 | Change | 1.84% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-21-26 | Upgrade | Northland Capital Markets | Market Perform → Outperform | |
| Oct-23-25 | Reiterated | Northland Securities | Market Perform | $110 → $95 |
| Jan-29-25 | Downgrade | Oppenheimer | Outperform → Perform | |
| Oct-30-24 | Reiterated | Northland Capital Markets | Market Perform | $100 → $110 |
| Oct-30-24 | Reiterated | Craig-Hallum | Buy | $138 → $113 |
| Oct-29-24 | Reiterated | HC Wainwright & Co. | Buy | $96 → $156 |
| Jul-31-24 | Reiterated | Craig-Hallum | Buy | $92 → $138 |
| May-22-24 | Reiterated | Oppenheimer | Outperform | $125 → $160 |
| Apr-18-24 | Reiterated | Oppenheimer | Outperform | $125 |
| Feb-02-23 | Reiterated | Roth Capital | Buy | $94 |
Latest News· Times ET
Nov-02-26
08:31AM
Transcat to Attend Upcoming Investor Conferences in Novemberbusinesswire.com
Oct-29-26
Oct-29-2608:50PM
01:11PM
Oct-27-26
Oct-21-26
Oct-20-26
08:31AM
Oct-14-26
Sep-29-26
Sep-23-26
Sep-23-2607:54PM
Sep-22-26
Sep-16-26
Sep-16-2611:10AM
Sep-14-26
Sep-08-26
Company
Transcat, Inc. is a provider of accredited calibration and laboratory instrument services, and a value-added distributor of professional grade test, measurement, and control instrumentation. The company operates through two segments, Service and Distribution, and focuses on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceutical, biotechnology, and medical device businesses.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2026 3/28/2026 | FY 2025 3/29/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 348 | 332 | 278 | 259 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 236 | 224 | 189 | 176 | — | — | — | — | — | |
| Gross Profit | 113 | 108 | 89 | 84 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 103 | 95 | 72 | 64 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 11 | 13 | 18 | 20 | — | — | — | — | — | |
| Interest Expense | 6 | 5 | 1 | 2 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1 | 0 | 1 | 0 | — | — | — | — | — | |
| Net Income Before Taxes | 6 | 8 | 18 | 18 | — | — | — | — | — | |
| Income Taxes | 3 | 3 | 4 | 5 | — | — | — | — | — | |
| Consolidated Net Income | 3 | 5 | 15 | 14 | — | — | — | — | — | |
| Net Income From Continuing Operations | 3 | 5 | 15 | 14 | — | — | — | — | — | |
| Net Income | 3 | 5 | 15 | 14 | — | — | — | — | — | |
| EPS (Recurring) | 0.37 | 0.58 | 1.58 | 1.66 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.37 | 0.58 | 1.58 | 1.66 | — | — | — | — | — | |
| EPS (Diluted) | 0.37 | 0.57 | 1.57 | 1.63 | — | — | — | — | — | |
| EBITDA | 39 | 39 | 38 | 34 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 242.00 | 125.12 | 46.74 | 68.36 | — | — | — | — | — | |
| Price To Sales Ratio | 2.32 | 1.93 | 2.38 | 3.44 | — | — | — | — | — | |
| Gross Margin | 32.47 | 32.53 | 32.01 | 32.43 | — | — | — | — | — | |
| Operating Margin | 3.16 | 3.92 | 6.47 | 7.72 | — | — | — | — | — | |
| Net Margin | 0.86 | 1.51 | 5.40 | 5.41 | — | — | — | — | — | |
| Shares Outstanding | 9 | 9 | 9 | 8 | — | — | — | — | — | |
| Market Capitalization | 806 | 642 | 660 | 891 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gillette Christopher P. | Director | Sep 10 '26 | Option Exercise | 0.00 | 1,587 | 0 | 1,787 | Sep 10 |
| Mecca Robert | Director | Sep 10 '26 | Option Exercise | 0.00 | 1,587 | 0 | 2,291 | Sep 10 |
| Dominach Oksana S. | Director | Sep 10 '26 | Option Exercise | 0.00 | 1,587 | 0 | 5,933 | Sep 10 |
| Kaniki Mbago M. | Director | Sep 10 '26 | Option Exercise | 0.00 | 1,587 | 0 | 4,180 | Sep 10 |
| DePerrior Dawn | Director | Sep 10 '26 | Option Exercise | 0.00 | 1,587 | 0 | 2,291 | Sep 10 |
| Haseley Gary J. | Director | Sep 10 '26 | Option Exercise | 0.00 | 1,587 | 0 | 40,689 | Sep 10 |
| Cairns Craig D. | Director | Sep 10 '26 | Option Exercise | 0.00 | 1,587 | 0 | 6,590 | Sep 10 |
| Langston Cynthia | Director | Sep 10 '26 | Option Exercise | 0.00 | 1,587 | 0 | 3,424 | Sep 10 |
| Dominach Oksana S. | Director | Sep 02 '26 | Sale | 85.60 | 7,312 | 625,876 | 4,346 | Sep 03 |
| Dominach Oksana S. | Director | Aug 13 '26 | Option Exercise | 26.27 | 10,000 | 262,700 | 14,346 | Aug 17 |
| Gillette Christopher P. | Director | Aug 07 '26 | Sale | 94.23 | 504 | 47,494 | 200 | Aug 12 |
| Cairns Craig D. | Director | Aug 06 '26 | Buy | 93.97 | 1,050 | 98,663 | 1,480 | Aug 10 |
| Rudow Lee D. | President and CEO | Mar 28 '26 | Option Exercise | 0.00 | 7,952 | 0 | 104,838 | Jun 11 |
| Rudow Lee D. | President and CEO | Mar 26 '26 | Option Exercise | 0.00 | 5,000 | 0 | 98,753 | Jun 11 |
| West Michael W. | Chief Operating Officer | Mar 28 '26 | Option Exercise | 0.00 | 725 | 0 | 26,823 | Apr 01 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.